Business
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held January 8-
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U8Q3xNkSuAPosRUnHeWZmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026","length":133,"tagName":"p"},{"type":"text","content":"JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held January 8-10, 2026 in San Francisco, California. The abstracts, entitled “Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study”, and “Inflammatory and Immune Marker Dynamics following Intratumoral Alpha DaRT for Pancreatic Cancer”, will both be presented by investigators in the Company’s recently completed pancreatic cancer pilot trial in Montreal, Canada, by study Principal Investigator Corey Miller, MD, and by Kim Anh Ma, MD, respectively.","length":894,"tagName":"p"},{"type":"text","content":"“I am delighted that exciting additional pancreatic cancer study data will be presented for a second consecutive year at the prestigious ASCO symposium with two abstracts,” commented Company CEO Uzi Sofer. “Following last year’s fantastic presentation, it is gratifying to be able to continue to demonstrate our acceleration in this important indication to top experts in the field, and to see our data being the subject of multiple presentations. I look forward to fascinating and engaging discussions.”","length":504,"tagName":"p"},{"type":"text","content":"Alpha Tau treated the first patient in its U.S. multi-center pancreatic cancer clinical trial in September 2025. The trial is expected ...